24 NOV 2023 | Celltrion Applies For EU Approval of CT-P42, Biosimilar to Regeneron’s Eylea® (aflibercept) Celltrion revealed in a corporate filing with the Repository of Korea’s...
BioBlast w/e 24 Nov 23
read more
Chris Vindurampulle PhD recognised as 2023 MIP Rising Star & Donna Meredith honoured.
Pearce IP is proud to announce that Executive Patent & Trade Mark Attorney Chris Vindurampulle PhD has been honoured as a Rising Star by Managing IP’s 2023 IP Stars. The MIP...
“Essence or Core” of an invention – Full Court adds non-statutory element to sufficiency in first appellate decision post-RTB
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 17 Nov 23
16 NOV 2023 | US | Approval Alert: AZ’s Truqap® (capivasertib) plus Faslodex® FDA Approved to Treat Advanced HR-positive Breast Cancer AstraZeneca (AZ) announced the FDA...
Confectionary chronicles: glucose jelly bean trade mark application appealed
On 9 August 2023, the Registrar of Trade Marks handed down a decision in favour of Nova Pharmaceuticals Australasia Pty Ltd (Nova) regarding its GLUCO BOOST trade mark in an...
Pearce IP – The only leading ANZ IP firm with a Female Founder, now certified as Women Owned
Managing IP (MIP) has honoured Pearce IP as the only known ANZ IP firm founded by a woman. Separately, WEConnect International has certified Pearce IP as Women Owned. CEO and...
BioBlast w/e 10 Nov 23
10 NOV 2023 | EU | CHMP Positive Opinion for 8mg Eylea® (Aflibercept) Bayer announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended...
Generics take Sandoz Rivaroxaban Loss to Heart – Bayer’s Rivaroxaban Patents Valid & Sandoz AU Launch Delayed by Injunction (Appeal Pending)
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BREAKING NEWS: Bayer Rivaroxaban patents survive first AU challenge by Sandoz with ~150 generic products approved
With over 150 rivaroxaban products approved (9 of them for Bayer), the outcome of the Sandoz challenge to the validity of the AU Bayer (Xarelto®) patents may be the case with the...
BioBlast w/e 03 Nov 23
01 NOV 2023 | EU | Fresenius Kabi’s Launches First EU Tocilizumab Biosimilar Fresenius Kabi announced it has launched Tyenne®, the first EC-approved biosimilar to Roche’s...
A hard lesson learnt: Commonwealth v Sanofi
The Australian government has made numerous claims for damages against patentees for savings forgone when an interlocutory/preliminary injunction (PI) delays generic launch but...
BioBlast w/e 27 Oct 23
27 OCT 2023 | US | Sanofi to Spin-Off Consumer Business and Focus on Biopharma by End Q4 2023 Sanofi announced that it will separate its Consumer Healthcare Business as soon as...
Special Counsel Julie Ballance joins Pearce IP as it expands into New Zealand
Pearce IP is delighted to announce that leading intellectual property specialist Julie Ballance (Patent Attorney, Lawyer and Notary, NZ) commenced with Pearce IP as a Special...
BioBlast w/e 23 Oct 23
23 OCT 2023 | US | Approval Alert: FDA Approves Celltrion’s Zymfentra® (infliximab-dyyb), Biosimilar to Janssen’s Remicade®, and the First Approved SC Infliximab...
BioBlast w/e 15 Oct 23
15 OCT 2023 | Samsung Bioepis Reveals SB16 (denosumab) Study Results at ASBMR Samsung Bioepis presented new data on its SB16 (denosumab, biosimilar to Amgen’s Prolia®) at the...
Advanta succeeds again in second extension of time application opposed by Nufarm
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Breakthrough Mining Innovator Globaltech wins AU Patent Battle against Market Leader Reflex
An Australian Court has found in favour of Globaltech which solved a mining problem with an elegant solution. An important lesson from this decision is that driving IP innovation can be central to maintaining a market-leading position.
BioBlast w/e 07 Oct 23
07 OCT 2023 | Samsung Bioepis Presents Switching Study Results for SB15, Biosimilar to Regeneron’s Eylea® (aflibercept) Samsung Bioepis announced its Phase III switching study...
When perceiving the problem is the inventive step – complacent market leader Reflex infringes disruptor Globaltech’s valid patent
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 02 Oct 23
02 OCT 2023 | Nobel Prize Awarded to Katalin Karikó and Drew Weissman for Their Work Which Supported the mRNA COVID-19 Vaccine The Nobel Assembly at Karolinska...
Zoetis Vaccine Patent Survives Opposition Appeal by the Hair of its Chinny Chin Chin
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 22 Sep 23
22 SEP 2023 | KR | Prestige Biologics Partners with Dr. Reddy’s Laboratories Subsidiary in Strategic Manufacturing Collaboration Prestige Biologics, a contract development and...
BioBlast w/e 15 Sep 23
15 SEP 2023 | US | Novartis Shareholders Approve Sandoz Spin-Off On 15 September 2023, Novartis shareholders approved the proposed Sandoz spin-off, Novartis’ generics and...
Federal Court Shines Light on Patent Litigation Case Management
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.